Important Notice To Researchers- Kindly Specify SARS-CoV-2 Variant Type Used When Publishing In Vitro, Vivo or Clinical Studies On Prophylactics or Therapeutics Agents
Source: Medical News - Research Nov 26, 2021 10 months ago
Researchers when conducting and submitting papers for publishing with regards to potential prophylactics and therapeutics should also mention the type of strains or variants of SARS-Cov-2 used in their studies as it is now clearly emerging that different strains and variants have different characteristics and even pathogenesis modes.
Even in the case of antivirals targeting the Mpro proteins for instance, we now have strains and variants that are resistant to certain therapeutics.
For example there are already strains resistant to remdesivir.
Are there any researchers out there that can do an analysis involving a large number of patients, analyzing their detailed immune profile including all CD markers, serological and cellular HLA specificities, cytokines and chemokines and receptors, before and after a SARS-CoV-2 infection over a six month period and also for those before and after COVID-19 vaccination over a six month period with careful emphasis on T cells like CD4, CD 8 and CD 25, CD16 monocytes, proteins CD 19 and CD 47 etc. Such data will provide very interesting insights. We have done for a group of only 8 patients ie 4 of 2 sets ie one for infection and another for vaccination and the data is extremely interesting to date.
Should anyone wish to contact us, please use the contact form on the site.